International Seminars in Physiology Series: Lecture by Dr. Javier Ruiz-Ederra

International Seminars in Physiology Series – Seminar Announcement
International Seminars in Physiology Series – Seminar Announcement

Date: Wednesday, December 3rd, 2025
 Time: 15:00 (Greece time)
 Location: Online (Zoom)
 Speaker: Dr. Javier Ruiz-Ederra
 Affiliation: University of the Basque Country (UPV/EHU) & Biogipuzkoa Health Research Institute
 Title of Talk: RyR calcium channel modulator, MP-004, as a novel therapeutic approach for retinitis pigmentosa

Announcement

As part of the International Seminars in Physiology Series, established in February 2024, we are pleased to host Dr. Javier Ruiz-Ederra for the fifth seminar of the academic year 2025–2026. Dr. Ruiz-Ederra is a leading researcher in sensory neurodegeneration and an Associate Professor in the Department of Ophthalmology at the University of the Basque Country (UPV/EHU).

His talk, titled “RyR calcium channel modulator, MP-004, as a novel therapeutic approach for retinitis pigmentosa”, will present emerging evidence on targeted therapeutic strategies for hereditary retinal dystrophies, aiming to advance translational research in ophthalmology.

The seminar will include a 45-minute presentation, followed by 15 minutes of discussion.

Zoom Meeting Information

Link:
 https://zoom.us/j/93962865330?pwd=4fiNWvZcmnbGam9jK3FwO2RqRlaH0B.1

Meeting ID: 939 6286 5330
 Passcode: 662917

About the Speaker

Dr. Javier Ruiz-Ederra leads the Sensory Neurodegeneration Research Group at the Biogipuzkoa Health Research Institute. His research focuses on ocular diseases—particularly hereditary retinal dystrophies—with an emphasis on innovative diagnostic tools and therapeutic development.

He conducted postdoctoral research at the University of California, San Francisco (2004–2009), studying aquaporins and ion channels in models of ocular pathology. After returning to Spain, he established an independent research program through a prestigious Miguel Servet tenure-track contract.

In 2019, he co-founded Miramoon Pharma, a spin-off dedicated to therapeutic innovation in inherited retinal disorders, contributing to a patent application (EP22382594) and achieving orphan drug designation from both the FDA and EMA.

Dr. Ruiz-Ederra has led 21 research projects, authored 30 peer-reviewed publications, supervised six PhD theses, and currently mentors three doctoral candidates. He is an active member of the European COST Action Retina4Future.